Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bb21217 in Relapsed/Refractory Multiple Myeloma
NCT03274219Phase 1Completed
- Sponsor
- 2seventy bio
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bb21217 in multiple myeloma (MM), sponsored by 2seventy bio. Primary endpoints: Incidence of Adverse Events and Dose Limiting Toxicities. Started Aug 2017; status: completed.
02
Drugs
bb21217
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03274219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274219.